CSH2 and cancer: Finally, we included the relatively uncharacterized ALL mutation Q510K, the R138Q mutation found in melanoma and other cancers, which ablates C-SH2 binding capability, and T507K, which disrupts auto-inhibition, alters substrate specificity, and has been observed in neuroblastoma, glioblastoma, and hepatocellular carcinoma1–3,19,47.